30 March 2007
Serum magnesium and calcium ions in patients with severe pre-eclampsia/eclampsia undergoing magnesium sulfate therapy
Shahnaz Aali, Payam Khazaeli, Fatemeh Ghasemi, Anahita MehdizadehMed Sci Monit 2007; 13(4): CR191-194 :: ID: 481104
Abstract
Background:Magnesium sulfate is used for seizure therapy and prophylaxis in women with eclampsia and pre-eclampsia worldwide. Magnesium may act by opposing calcium-dependent arterial constriction and may also antagonize the increase in intracellular calcium concentration. The objectives were to study the alterations in serum ionized magnesium and calcium and their relationship in patients with severe pre-eclampsia/eclampsia receiving magnesium sulfate therapy.
Material/Methods:Fifty patients in singleton pregnancy with severe pre-eclampsia or eclampsia who were candidates for intravenous magnesium sulfate infusion were studied. Serum ionized magnesium and calcium concentration were determined in blood samples taken before magnesium sulfate infusion, 30 and 240 minutes after the initiation of the infusion, and 4 hours after discontinuation of the therapy. Repeated-measure ANOVA, paired t-test, and Pearson’s correlation coefficient were used to analyze the data.
Results:Mean baseline levels of ionized magnesium and ionized calcium were 1.3±0.5 mEq/l and 3.8±0.5 mg/dl, respectively. The mean concentration of ionized magnesium changed significantly at the stated intervals, while mean ionized calcium values did not. Significant correlation was found between ionized calcium and magnesium four hours after the initiation of magnesium sulfate infusion and after discontinuation of the therapy.
Conclusions:Magnesium ion does not appear to exert its therapeutic effect in pre-eclampsia/eclampsia by substantially modulating serum ionized calcium. However, the effect of exogenous Mg on intracellular calcium cannot be ruled out.
Keywords: Analysis of Variance, Calcium - blood, Eclampsia - drug therapy, Magnesium - blood, Magnesium Sulfate - therapeutic use, Pre-Eclampsia - drug therapy, Pregnancy, Time Factors
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952